“药王”更迭,替尔泊肽年销售额超365亿美元登顶

新京报
Feb 12

近期,全球各大药企相继披露2025年财报,2025年全球畅销药中,销售额超百亿美元的品种相继出炉。诺和诺德旗下黑马司美格鲁肽在2025年一季度反超默沙东的帕博利珠单抗(俗称“K药”)后,短暂登顶“药王”,但最终被礼来的替尔泊肽反超。三款药2025年销售额均超300亿美元。此外,百时美施贵宝(BMS)的纳武利尤单抗(俗称“O药”)、强生的达雷妥尤单抗、艾伯维的利生奇珠单抗、赛诺菲的度普利尤单抗、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10